1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
DermTech, Inc.

DermTech, Inc.

DMTKQ
DermTech, Inc.US flagOther OTC
0.00
USD
- -
- -
3,496.00Market Cap
2016 Y
2017 Y
2018 Y
2019 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
- -
- -
- -
- -
0.48
0.35
0.41
0.48
0.47
0.47
Basic EPS, GAAP
- -
- -
0.36
0.37
-2.87
-2.15
-2.71
-3.88
-3.09
-2.66
Free Cash Flow per Basic Share
- -
- -
-0.16
-0.17
-2.57
-1.8
-2.24
-3.28
-2.39
-2.15
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
0.01
60.08
2.28
-13.01
-7.54
-7.14
-10.75
-12.99
-13.19
Tangible Book Value per Share
- -
0.01
60.08
2.28
1.78
3.64
7.95
4.41
1.75
1.19
Basic Weighted Avg Shares
- -
2
2
3
7
17
29
30
33
34
Sales/Revenue/Turnover
- -
- -
- -
- -
3
6
12
15
15
16
Operating Margin (%)
- -
- -
- -
- -
-523.34
-599.64
-653.81
-813.92
-678.21
-588.62
Depreciation Expense
- -
- -
- -
- -
- -
- -
2
4
6
6
Net Income, GAAP
- -
- -
1
1
-20
-36
-78
-117
-101
-90
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
-598.39
-619.83
-661.72
-803.71
-659.57
-572.19
Working Capital
- -
- -
1
-1
11
61
221
120
48
32
LT Debt
- -
- -
- -
- -
- -
- -
6
54
51
50
Total Equity
- -
- -
142
6
12
62
230
132
57
40
Return on Invested Capital (%)
- -
- -
-0.43
-2.68
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
1.21
1.28
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-0.27
1.21
1.28
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'23
Dec'23
Mar'24
ST Debt
3
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
52
51
50
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
34
35
35
Market Capitalization
46
57
24

Working Capital

FRC

•

in mil. unless spec.
Sep'23
Dec'23
Mar'24
Total Current Assets
76
62
44
Cash, Cash Equivalents & STI
68
56
39
Accounts Receivable, Net
4
3
2
Inventories
1
1
1
Total Current Liabilities
13
13
13
Payables & Accruals
3
6
6
ST Debt
3
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
136.18%
-56.8%
Free Cash Flow
- -
832.63%
-20.99%
Net Income, GAAP
- -
-400%
-13.54%
Sales/Revenue/Turnover
- -
- -
5.36%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
4
4
4
3
15
2023
3
4
4
4
15
2024
4
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-1.01
-0.99
-0.96
-0.93
-3.88
2023
-1.02
-0.99
-0.57
-0.56
-3.09
2024
-0.58
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Burkhard Jansen
Full Time Employees
206
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
12340 El Camino Real San Diego CA United States of America 92130
IPO Date
Aug 10, 2017
CIK
0001651944
Website
dermtech.com
Similar Companies
Imagion Biosystems Limited (IBX.AX)
Suraksha Diagnostic Limited (SURAKSHA.NS)
BioNano Genomics, Inc. WT EXP 082123 (BNGOW)
Sera Prognostics, Inc. (SERA)
Telo Genomics Corp. (TDSGF)
Polski Bank Komórek Macierzystych S.A. (BKM.WA)
Business
DermTech, LLC, now a private entity in precision dermatology, offers advanced non-invasive genomics solutions for skin assessment. The company's core offering is the DermTech Melanoma Test (DMT), designed to enhance the detection and management of melanoma through a non-surgical approach. This innovative method utilizes Smart Stickers for collecting skin samples, providing a less intrusive alternative to traditional scalpel biopsies for suspicious lesions. The test demonstrates a high negative predictive value for ruling out melanoma. Previously operating as DermTech, Inc., the company initiated a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware on June 18, 2024. Following this, substantially all of its assets were acquired by DERM-JES Holdings, LLC in August 2024, resulting in the establishment of DermTech, LLC. The new organization continues its laboratory operations and processes orders for the DermTech Melanoma Test from its headquarters in San Diego, California.

Company News

APIChat

  • globenewswire.com

    DERMTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating DermTech, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm